Commercial Medical Devices

Cross-Party Lords Push Value-Based NHS Procurement

Peers urged the NHS to weigh patient outcomes and long-term costs, not just purchase price, as questions surfaced over standardised product lists.

Sonia MarchettiNovember 5, 20265 min read1 views
An editorial illustration of a clinician and a procurement specialist comparing a personalised medical device with standard supplies in a hospital setting.

The NHS is being urged to look beyond the sticker price of medical products and consider whether higher upfront spending can improve patient care and reduce long-term costs, after value-based procurement drew cross-party support in the House of Lords.

The issue arose during debate on the Health Bill, where peers considered an amendment tabled by Labour’s Lord Hunt of Kings Heath and supported by crossbench peer Baroness Finlay of Llandaff. The amendment would require ministers to report annually to Parliament on progress toward adopting value-based procurement across the NHS and social care in England.

Value-based procurement assesses patient outcomes, clinical benefits and the wider costs of care rather than only the initial purchase price. The approach is already being introduced across the health service after national guidance was published in June.

Pilot cited as evidence

Lord Hunt, a former health minister and longstanding advocate, welcomed progress. He said procurement exists to secure value for money but can do more, and argued the focus should move away from always choosing the lowest price toward quality that improves patient outcomes.

He cited a pilot at South Tyneside and Sunderland NHS Foundation Trust, conducted with health and hygiene company Essity. Providing continence products suited to patients’ individual needs led to a 48% reduction in leaks and an 8% fall in product use, he said.

Baroness Finlay, a professor of palliative medicine, praised the work of the Department of Health and Social Care’s Medical Technology and Innovation Directorate and called for wider adoption across the NHS and social care. She argued cheaper equipment can be a false economy if it leads to complications or further treatment, with costs falling on different NHS budgets. Specialist cardiac pacemakers, she said, illustrated how more expensive devices could help prevent serious infections in vulnerable patients and potentially avoid costly intensive care.

“It is the clinicians who know that the cheapest is not necessarily the best,” she said, adding that clinicians understand outcomes for particular devices and that this needs to be embedded in tendering.

Political support and purchasing concerns

Former Health Secretary Lord Lansley, a Conservative peer, also backed the proposals but warned rigid pricing thresholds could stop more expensive products from being properly assessed for wider benefits. Liberal Democrat health spokesperson Lord Scriven called the national guidance a “genuine step forward” but cautioned that financial pressures could still push NHS buyers toward immediate savings over better long-term outcomes.

Health minister Baroness Merron reaffirmed the government’s commitment to value-based procurement and said NHS Supply Chain had adopted a “comply or explain” approach for future purchasing frameworks. She said the intention was for value-based procurement to become routine practice when NHS teams buy medical devices, consumables and services. The government has commissioned independent monitoring, with annual reports over the next three years to assess the guidance’s impact.

The debate also exposed concerns about whether existing purchasing practices fit the policy. Lord Hunt questioned NHS Supply Chain’s recent decision to identify 79 additional product categories for potential inclusion in its Core List of standardised supplies, including urinary catheters and colostomy bags. He warned that these are highly personal products rather than standard commodities and criticised the lack of prior consultation with relevant trade associations.

Baroness Merron acknowledged the importance of products being tailored to individual patients but did not directly address the proposed Core List expansion, leaving questions over how the NHS will balance greater standardisation with clinically led, patient-centred procurement.

Chris Whitehouse, a health policy lobbyist whose agency Whitehouse Communications worked on the amendment with Essity, said there was now broad cross-party support for value-based procurement and a real desire to see it rolled out with momentum across the NHS in England.